PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 3, 2026Clinical and Experimental Dermatology1 citations

Bimekizumab for treatment of moderate to severe hidradenitis suppurativa: A real-world, single centre case series

View Full Paper
EPEmily PenderECEmma CarrollMVMaria-Alexandra Visan

Key Points

  • Evaluate the effectiveness of bimekizumab in patients with moderate to severe hidradenitis suppurativa.
  • Single-center case series
  • Assess response rates at week 16
  • Examine previous biologic exposure in patients
  • Response rates at week 16 are higher than in phase III clinical trials
  • All patients had previous biologic exposure
  • Concomitant HS medication may influence results

Abstract

Response rates in this group at week 16 are higher than those seen in phase III clinical trials, despite previous biologic exposure in all patients. While concomitant HS medication may play a role in this higher response rate, bimekizumab is an important treatment option for moderate-to-severe HS.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Pender et al. (2026) studied this question.

synapsesocial.com/papers/69cf5cd15a333a821460a5dehttps://doi.org/10.1093/ced/llag140
Ask AI
Helpful
Bookmark
Share
View Full Paper